A novel hepatitis B virus surface antigen immunoassay as sensitive as hepatitis B virus nucleic acid testing in detecting early infection

Transfusion

Volumn 49, Issue 3, 2009, Pages 585-595

  Matsubara, Naoko ^a   Kusano, Osamu ^b   Sugamata, Yasuhiro ^b   Itoh, Tetsuo ^b   Mizuii, Masaaki ^b   Tanaka, Junko ^b   Yoshizawa, Hiroshi ^b  

^a FUJIREBIO INC   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; MONOCLONAL ANTIBODY; NUCLEIC ACID; VIRUS DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN DETECTION; ARTICLE; CHEMOLUMINESCENCE; CHIMPANZEE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; HEPATITIS B; HEPATITIS B VIRUS; NONHUMAN; POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; SEROCONVERSION; VIREMIA;

ANIMALS; DNA, VIRAL; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; IMMUNOASSAY; INDICATOR DILUTION TECHNIQUES; MICE; MICE, INBRED BALB C; MODELS, BIOLOGICAL; PAN TROGLODYTES; SUBSTRATE SPECIFICITY; TIME FACTORS;

EID: 60149096594     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2008.02026.x     Document Type: Article

References (42)

1. World Health Organization. Hepatitis B. Geneva : WHO 2002. [cited 2008 July]. Available from: http://www.who.int/csr/disease/hepatitis/HepatitisB- whocdscsrlyo2002-2.pdf
2. Lee WM. Hepatitis B virus infection. N Engl J Med 1997 337 : 1733 45.
3. But DY, Lai CL, Yuen MF. Natural history of hepatitis-related hepatocellular carcinoma. World J Gastroenterol 2008 14 : 1652 6.
4. Pan CQ, Zhang JX. Natural history and clinical consequences of hepatitis B virus infection. Int J Med Sci 2005 2 : 36 40.
5. Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 2001 115 : 58 62.
6. Chan TM, Fang GX, Tang CS, Cheng IK, Lai KN, Ho SK. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology 2002 36 : 1246 52.
7. Pungpapong S, Kim WR, Poterucha JJ. Natural history of hepatitis B virus infection: an update for clinicians. Mayo Clin Proc 2007 82 : 967 75.
8. Liang R, Lau GK, Kwong YL. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol 1999 17 : 394 8.
9. Marusawa H, Imoto S, Ueda Y, Chiba T. Reactivation of latently infected hepatitis B virus in a leukemia patient with antibodies to hepatitis B core antigen. J Gastroenterol 2001 36 : 633 6.
10. Okada K, Kamiyama I, Inomata M, Imai M, Miyakawa Y. e antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants. N Engl J Med 1976 294 : 746 9.
11. Beasley RP, Trepo C, Stevens CE, Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol 1977 105 : 94 8.
12. Yoshizawa H. Trends of hepatitis virus carriers. Hepatol Res 2002 24 Suppl 1 : S28 39.
13. Lupberger J, Hildt E. Hepatitis B virus-induced oncogenesis. World J Gastroenterol 2007 13 : 74 81.
14. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001 37 Suppl 8 : S4 66.
15. Liu CJ, Kao JH. Hepatitis B virus-related hepatocellular carcinoma: epidemiology and pathogenic role of viral factors. J Chin Med Assoc 2007 70 : 141 5.
16. Diepersloot RJ, van Zantvliet-van Oostrom Y, Gleaves CA. Comparison of a chemiluminescent immunoassay with two microparticle enzyme immunoassays for detection of hepatitis B virus surface antigen. Clin Diagn Lab Immunol 2000 7 : 865 6.
17. Ly TD, Servant-Delmas A, Bagot S, Gonzalo S, Férey MP, Ebel A, Dussaix E, Laperche S, Roquw-Afonso AM. Sensitivities of four new commercial hepatitis B virus surface antigen (HBsAg) assays in detection of HBsAg mutant forms. J Clin Microbiol 2006 44 : 2321 6.
18. Linauts S, Saldanha J, Strong DM. PRISM hepatitis B surface antigen detection of hepatitis B virus minipool nucleic acid testing yield samples. Transfusion 2008 48 : 1376 82.
19. Kuhns MC, Busch MP. New strategies for blood donor screening for hepatitis B virus: nucleic acid testing versus immunoassay methods. Mol Diagn Ther 2006 10 : 77 91.
20. Soldan K, Davison K, Dow B. Estimates of the frequency of HBV, HCV, and HIV infectious donations entering the blood supply in the United Kingdom, 1996 to 2003. Euro Surveill 2005 10 : 17 9.
21. Offergeld R, Faensen D, Ritter S, Hamouda O. Human immunodeficiency virus, hepatitis C and hepatitis B infections among blood donors in Germany 2000-2002: risk of virus transmission and the impact of nucleic acid amplification testing. Euro Surveill 2005 10 : 8 11.
22. Pillonel J, Laperche S. Trends in risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2003 and impact of nucleic acid testing (NAT). Euro Surveill 2005 10 : 5 8.
23. Hoofnagle J. Post-transfusion hepatitis B. Transfusion 1990 30 : 384 6.
24. Romanó L, Velati C, Baruffi L, Fomiatti L, Colucci G, Zanetti AR. Multicenter evaluation of a semiautomated, standardized assay for detection of hepatitis B virus DNA in blood donations. J Clin Microbiol 2005 43 : 2991 3.
25. Niederhauser C, Mansouri Taleghani B, Graziani M, Stolz M, Tinguely C, Schneider P. Blood donor screening: how to decrease the risk of transfusion-transmitted hepatitis B virus? Swiss Med Wkly 2008 138 : 134 41.
26. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005 5 : 215 29.
27. Weber B, Bayer A, Kirch P, Schlüter V, Schlieper D, Melchior W. Improved detection of hepatitis B virus surface antigen by a new rapid automated assay. J Clin Microbiol 1999 37 : 2639 47.
28. Biswas R, Tabor E, Hsia CC, Wright DJ, Laycock ME, Fiebig EW, Peddada L, Smith R, Schreiber GB, Epstein JS, Nemo GJ, Busch MP. Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. Transfusion 2003 43 : 788 98.
29. Wiedmann M, Kluwick S, Walter M, Fauchald G, Howe J, Bronold M, Zauke M. HIV-1, HCV and HBV seronegative window reduction by the new Roche cobas® TaqScreen MPX test in seroconverting donors. J Clin Virol 2007 39 : 282 7.
30. Komiya Y, Katayama K, Yugi H, Mizui M, Matsukura H, Tomoguri T, Miyakawa Y, Tabuchi A, Tanaka J, Yoshizawa H. Minimum infectious dose of hepatitis B virus in chimpanzees and difference in the dynamics of viremia between genotype A and genotype C. Transfusion 2008 48 : 286 94.
31. Ozaras R, Tabak F, Tahan V, Ozturk R, Akin H, Mert A, Senturk H. Correlation of quantitative assay of HBsAg and HBV DNA levels during chronic HBV treatment. Dig Dis Sci 2008 53 : 2995 8.
32. Avrameas S. Coupling of enzymes to proteins with glutaraldehyde. Use of the conjugates for the detection of antigens and antibodies. Immunochemistry 1969 6 : 43 52.
33. Howard CR, Stirk HJ, Brown SE, Steward MW. Towards the development of synthetic hepatitis B vaccines. In : Zuckerman AJ, editor. Viral hepatitis and liver disease. New York : A. R. Liss Inc., 1988. p. 1094 101.
34. Aoyagi K, Miyake Y, Urakami K, Kashiwakuma T, Hasegawa A, Kodama T, Yamaguchi K. Enzyme immunoassay of immunoreactive progastrin-releasing peptide (31-98) as tumor marker for small-cell lung carcinoma: development and evaluation. Clin Chem 1995 41 : 537 43.
35. Brown SE, Howard CR, Zuckerman AJ, Steward MW. Determination of the affinity of antibodies to hepatitis B surface antigen in human sera. J Immunol Methods 1984 72 : 41 8.
36. Brown SE, Howard CR, Zuckerman AJ, Steward MW. Affinity of antibody responses in man to hepatitis B vaccine determined with synthetic peptides. Lancet 1984 2 (8396 184 7.
37. Brown SE, Stanley C, Howard CR, Zuckerman AJ, Steward MW. Antibody responses to recombinant and plasma derived hepatitis B vaccines. BMJ (Clin Res Ed) 1986 292 : 159 61.
38. Carman WF. The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat 1997 4 Suppl 1 : 11 20.
39. Gerlich WH. Diagnostic problems caused by HBsAg mutants - a consensus report of an expert meeting. Intervirology 2004 47 : 310 3.
40. Coleman P. Detecting hepatitis B surface antigen mutants. Emerg Infect Dis 2006 12 : 198 203.
41. Blanpain C, Knoop C, Delforge ML, Antoine M, Peny MO, Liesnard C, Vereerstraeten P, Cogan E, Adler M, Abramowicz D. Reactivation of hepatitis B after transplantation in patients with pre-existing anti-hepatitis B surface antigen antibodies: report on three cases and review of the literature. Transplantation 1998 66 : 883 6.
42. Hui CK, Cheung WW, Leung KW, Cheng VC, Tang BS, Li IW, Luk JM, Lee NP, Kwong YL, Au WY, Yuen KY, Lau GK, Liang R. Outcome and immune reconstitution of HBV-specific immunity in patients with reactivation of occult HBV infection after alemtuzumab-containing chemotherapy regimen. Hepatology 2008 48 : 1 10.